Serum and Peritoneal Concentration in Antibiotics During the Surgical Management of Peritonitis
NCT ID: NCT03310606
Last Updated: 2019-01-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
50 participants
INTERVENTIONAL
2017-10-24
2019-05-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The aim of this study is to determine if the beta-lactam dosages recommended by the guidelines for management of intra-abdominal infections (published by the Société française d'anesthésie et de réanimation (Sfar) in december 2015) permitted the achievement of adequatly serum and peritoneal concentrations in the medical and surgical management of peritonitis.
The investigators will collected 3 pairs of serum and peritoneal fluid samples at 3 different times: peritoneal incision, arrival in ICU and 24 hours after admission in ICU in order to compare the concentrations and the minimal inhibitor concentration of bacteria.
The hypothesis is that of a serum and peritoneal antibiotic under dosage.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Peritoneal Diffusion and Efficacy of Antibiotic Therapy in Pediatric Peritonitis
NCT05308849
Is Spontaneous Bacterial Peritonitis Still Responding to 3rd Generation Cephalosporins?
NCT02443285
Duration of Antibiotic Therapy in the Treatment of Severe Postoperative Peritonitis Admitted in ICU
NCT01311765
Multicentre Observational Study on Community Acquired Intraabdominal Infections Management
NCT03544203
Procalcitonin as a Marker for the Length of Antibiotic Treatment in Peritonitis and Intra-abdominal Infections
NCT01155739
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Peritonitis
Patient received for antibiotic treatment a B lactam according to French recommendation :
* type of antibiotic : cefotaxime or ceftriaxone or piperacilline/tazobactam or imipenem
* dose : cefotaxime 2g / cetriaxone 2g / piperacilline 4g / imipenem 1g
Dosage of serum and peritoneal of the B lactam used for antibiotic treatment
Dosage of serum and peritoneal of the B lactam used B lactam concerning are : CEFTRIAXONE, CEFOTAXIME, PIPERACILLINE/TAZOBACTAM, IMIPENEM
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dosage of serum and peritoneal of the B lactam used for antibiotic treatment
Dosage of serum and peritoneal of the B lactam used B lactam concerning are : CEFTRIAXONE, CEFOTAXIME, PIPERACILLINE/TAZOBACTAM, IMIPENEM
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* All sex
* Patients with peritonitis (community or nosocomial) regardless of pathology involved
* Patients treated in the Universty Hospital of Vandoeuvre les Nancy (abdominal surgery unit and surgical Intensive care unit JM Picard)
Exclusion Criteria
* Pregnancy
* Age less than 18 years
* No respect of recommandations for antibiotics ( molecule and dosage)
* Person under legal protection
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Central Hospital, Nancy, France
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Emmanuel NOVY, MD
Role: PRINCIPAL_INVESTIGATOR
CHRU NANCY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Central Hospital
Vandœuvre-lès-Nancy, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Leon L, Guerci P, Pape E, Thilly N, Luc A, Germain A, Butin-Druoton AL, Losser MR, Birckener J, Scala-Bertola J, Novy E. Serum and peritoneal exudate concentrations after high doses of beta-lactams in critically ill patients with severe intra-abdominal infections: an observational prospective study. J Antimicrob Chemother. 2020 Jan 1;75(1):156-161. doi: 10.1093/jac/dkz407.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2017-A00710-53
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.